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Bipolar disorder is an illness of cyclic mood episodes that may be elevated, depressed,
or mixed. It affects 2.4% of the population worldwide.1 Episodes of mania or hypomania are characterized by elevated or irritable mood, decreased need for sleep,
grandiosity, pressured speech, increased goal-directed activities, high-risk behaviors,
distractibility, and flight of ideas.2 Depressive episodes are often indistinguishable
from symptom presentations in major depressive disorder, placing bipolar patients
at risk of misdiagnosis. All aspects of bipolar disorder can be significantly debilitating and interfere with activities of daily living, including interpersonal relationships,
and work productivity.

Adherence
One of the most pressing challenges in the treatment of bipolar disorder is the lack of
consistent medication adherence. Adherence has been broadly defined as the extent to
285

submit your manuscript | www.dovepress.com

Neuropsychiatric Disease and Treatment 2018:14 285–292

Dovepress

© 2018 Torres-Llenza et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/NDT.S129559

Powered by TCPDF (www.tcpdf.org)

Abstract: The lack of long-term medication adherence is a challenge in the treatment of
bipolar disorder, particularly during the maintenance phase when symptoms are less prominent.
The rate of nonadherence is ~20%–60% depending on how strict a definition is used. Nonadherence worsens the course of bipolar disorder and can add hundreds of thousands of dollars to
the lifetime cost of treating the illness. Long-acting injectable (LAI) medication is an attractive
alternative to daily dosing of oral medication, especially among patients who are ambivalent
about treatment. The purpose of this paper is to review the evidence for the safety and efficacy
of LAI aripiprazole, which was recently approved for the treatment of bipolar disorder. The
approval was based on a single double-blind, placebo-controlled, multisite trial that recruited
participants from 103 sites in 7 countries. A total of 731 participants with bipolar disorder were
enrolled in the study. Out of that total, 266 were successfully stabilized on LAI aripiprazole
and entered the randomization phase. Treatment-emergent adverse events were, for the most
part, mild to moderate. Akathisia was the most common adverse event, which, combined with
restlessness, was experienced by 23% of the sample. At the end of the 52-week study period,
nearly twice as many LAI-treated participants remained stable compared to those treated with
placebo. Stability during the maintenance phase is arguably the most important goal of treatment. It is during this period of relative freedom from symptoms that patients are able to build
a meaningful and satisfying life. The availability of a new treatment agent, particularly one that
has the potential to enhance long-term adherence, is a welcome development.
Keywords: antipsychotic, adherence, partial agonist, mood stabilizer, review
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which a person’s behavior coincides with medical advice;3,4
however, there is no single way of measuring it. It can be
quantified based on how many prescriptions are filled, the
degree to which a patient takes medication in the way it was
prescribed, or the percentage of prescribed doses that were
consumed, for example, $90%.
In bipolar disorder, nonadherence rates are between
20% and 60%.5 These rates depend on the definition of
nonadherence that is being used, as well as the duration of
the study and the characteristics of the patient population.6
Sajatovic et al retrospectively assessed adherence to
antipsychotic medication among a sample of veterans with
bipolar disorder.7 They defined adherence using the medication possession ratio (MPR), which is calculated based
on how many days’ worth of medication a patient actually
obtained divided by how many days he/she should have
been consuming it. An advantage of using this definition is
that the data needed to calculate it can be obtained from the
medical chart and pharmacy records, making it unnecessary
to interview each patient individually. The disadvantage
is that it does not take into account the fact that a patient
may have obtained a supply of pills and then failed to
take them.
Full adherence in this study was defined as an MPR
of $0.8. Partial adherence was defined as $0.5 to ,0.8 and
patients with an MPR of ,0.5 were classified as nonadherent.
The investigators found that approximately half of bipolar
veterans who were prescribed an antipsychotic medication
were nonadherent.
In a separate study, adherence was evaluated prospectively using an adherence scale with a range of 1–4 as follows:
1) the patient had not been prescribed a psychotropic
medication, 2) the patient almost always adhered to medication, 3) the patient adhered to the medication half of the
time, and 4) the patient almost never adhered to medication.6 By using a more narrow definition of nonadherence,
the authors found that ~24% of patients were nonadherent.
They also found higher total medical expenditures for the
nonadherent patients compared to those who adhered to the
prescribed regimen.
There are many causes of nonadherence, including poor
insight into the need for medication and concern about
adverse effects.4,8 Risk factors that increase the likelihood
of nonadherence include younger age, substance misuse,
homelessness, non-Caucasian ethnicity, being unmarried,
and living alone.7,9
As would be expected, nonadherence worsens the natural
course of the illness. Persons with bipolar disorder who are
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nonadherent are more likely to miss work, have a reduced
work schedule, and have more frequent emergency department visits.9 Nonadherence is a major risk factor for relapse,
hospital readmission, and suicidality.9
Nonadherence is also costly. Inpatient treatment for
mental disorders costs ~$6,000 per admission, with an
average length of stay of 8 days.10 Overall, annual medical
expenditures for bipolar disorder are between $8.5 billion and
$27.5 billion.11 On an individual basis, the average lifetime
cost is ~$252,000 ranging from $11,720 for patients with a
single manic episode to $625,000 in chronic patients and
those who do not improve with treatment, often a sign of
nonadherence.12 A European study found a twofold increase
in total costs for inpatient treatment among nonadherent
patients when compared to those who were adherent with
treatment.6 These additional costs can put significant stress
on the health care system because patients with mental or
substance-use disorders are twice as likely to be uninsured
compared to patients without these diagnoses.10
Despite the high cost of relapse in both financial and
human terms, pharmacologic options for maintaining stability are limited. Lithium continues to be the gold standard
treatment for bipolar disorder, especially during the maintenance phase;13 however, relapse continues to be the rule.
A systematic review found an average risk of relapse rate of
40% among bipolar patients taking lithium.14 While this rate
was significantly better than the 60% relapse rate associated
with placebo, it is still far from ideal.
Long-acting injectable (LAI) medication is an attractive
option given the high rates of nonadherence among bipolar
patients. The first LAI medication approved for the treatment of bipolar disorder was risperidone, and more recently
a formulation of LAI aripiprazole has received approval by
the Federal Drug Administration for this indication. This
article will review the evidence that supports the use of LAI
aripiprazole for the treatment of bipolar disorder.

Materials and methods
We conducted a literature search using the online engines
of Google Scholar, PubMed, and Medline. We searched for
studies using aripiprazole LAI for the treatment of bipolar
disorder. Keywords used included “bipolar,” “aripiprazole,”
“long-acting,” “injectable,” “LAI,” and “long-acting aripiprazole.” One clinical trial was identified that focused on the use
of LAI aripiprazole in bipolar disorder. Representative articles
were selected for illustrative purposes that more broadly
discussed the use of aripiprazole in bipolar disorder and LAI
aripiprazole for the treatment of psychiatric conditions.
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Results
Mechanism of action
Aripiprazole was discovered by scientists at Otsuka Pharmaceuticals and later licensed to Bristol-Myers Squibb for joint
development.15 The US Food and Drug Administration (FDA)
approved aripiprazole for the treatment of schizophrenia in
November 2002. Currently approved indications include the
treatment of schizophrenia, acute manic and mixed episodes
associated with bipolar I disorder, maintenance treatment of
bipolar I disorder, adjunctive treatment of major depressive
disorder, irritability associated with autism, Tourette’s disorder, and agitation associated with schizophrenia and bipolar
mania.16 LAI aripiprazole was approved for the treatment of
schizophrenia in 2013.17
Aripiprazole interacts with multiple receptors in the brain,
which may contribute to its specific clinical effects. It has
high affinity for dopamine D2 and D3 receptors and serotonin
5HT1A and 5HT2A receptors, and moderate affinity for dopamine D4 and serotonin 5HT2C and 5HT7 receptors.18 Each
of these receptor interactions will be briefly reviewed.
Aripiprazole was the first antipsychotic to use a partial
agonist strategy to modify the activity of the dopamine
system. Prior to its introduction, all antipsychotics blocked
the D2 receptor as antagonists, preventing dopamine, the
natural agonist, from binding and bringing about a conformational change that activated the receptor.
Unlike antagonists, partial agonists trigger a conformational change in the receptors they bind to, but the resulting
morphology of the receptor is different from the result of a full
agonist and leads to a lower level of activation.19 This intermediate effect allows aripiprazole to have some degree of functional
selectivity, meaning it can increase or decrease D2 receptor
activity depending on its environment.20 For example, if there
is dopamine overactivity, the partial agonist will displace the
full agonist and reduce the response. If, on the other hand,
there is a deficiency of dopaminergic activity, the partial
agonist will partly restore normal receptor functioning.21
Apart from its effects on psychosis, partial D2 agonism
may account for other effects of aripiprazole. In the tuberoinfundibular pathway, dopamine acts to suppress the release
of prolactin from the pituitary. A troublesome side effect of
antipsychotic medication is hyperprolactinemia that occurs
when dopamine is prevented from acting in this part of the
brain. Aripiprazole, on the other hand, tends to lower prolactin levels, and can be used to counteract hyperprolactinemia
caused by other antipsychotic medications.21 In terms of side
effects, agitation, anxiety, nausea, and insomnia may be due
to partial agonism at the D2 receptor.20

Neuropsychiatric Disease and Treatment 2018:14
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The dopamine D3 receptor, for which aripiprazole has
high affinity as a partial agonist, has been implicated in the
pathophysiology of schizophrenia, drug addiction, and mood
disorders.22 Dopamine D3 receptors are widely distributed
throughout the brain with high levels found in the limbic
system.22 Preclinical studies using cariprazine, another
atypical antipsychotic with high affinity to D3 receptors,
have found procognitive and mood-altering effects in rats.23,24
New D3 antagonists are being developed to treat addiction
and compulsive behavior disorders.23
Serotonin activity is also modulated by aripiprazole.
Aripiprazole acts as a partial agonist at the 5HT1A receptor,
which mediates inhibitory neurotransmission and is involved
in neurogenesis.25,26 Dense concentrations of 5HT1A receptors are found in limbic areas, such as the hippocampus, as
well as in the cortex, the midbrain and the raphe nuclei.27 Systemic administration of 5HT1A receptor agonists selectively
stimulates 5HT1A receptors located on gamma-aminobutyric
(GABA) neurons in the prefrontal cortex.28 This effect reduces
the activity of GABA neurons, disinhibiting excitatory glutamate neurons, which ultimately results in the activation
of mesocortical dopamine neurons and increased activity in
the frontal cortex.28 This mechanism suggests that 5HT1A
receptor agonism may improve cognition in schizophrenia.28
As with buspirone, which has a similar mechanism of action,
modulation of 5HT1A receptors also may reduce anxiety.29
Another way in which aripiprazole may increase dopaminergic neurotransmission is via antagonism of serotonin
5HT2A receptors.21,28 The clinical ramifications may include
effects on cognition and negative symptoms.
Aripiprazole is a weak partial agonist at the serotonin
5HT7 receptor. Dense concentrations of this receptor have
been found in the hypothalamus, thalamus, hippocampus,
brainstem, and cortex.30 Consistent with this anatomical distribution, evidence derived from animal studies have linked
5HT7 receptors to thermoregulation, learning, memory,
endocrine function, circadian rhythm, and sleep.27,30 Drugs
that stimulate 5HT7 receptors have been shown to induce
circadian phase shifts.27,31 In addition, selective 5HT7 antagonists given to animals increased the latency to rapid eye
movement (REM) sleep and decreased the amount of time
spent in REM sleep – the opposite of what is encountered in
depressed patients.31
Activity at the serotonin 5HT2C receptor appears to
have effects on feeding behavior, especially in conjunction
with histamine H1 receptor antagonism.21 Aripiprazole acts
as a partial agonist at 5HT2C. Per Disciasio, the antagonist
component of aripiprazole’s partial agonist activity at the
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serotonin 5HT2C receptor may be responsible for weight
gain. The explanation for this effect is based on the finding
that activation of 5HT2C results in increased satiety and
hypophagia in animal studies.32
Aripiprazole has varying effects on weight.33 Studies
that enrolled participants with schizophrenia did not find
significant weight gain associated with aripiprazole exposure.
However, when aripiprazole was used to augment serotonergic antidepressants for the treatment of refractory depression,
weight gain occurred significantly more frequently than with
placebo.34
As previously noted, aripiprazole is a partial agonist at
5HT2C. Nguyen et al hypothesize that aripiprazole may act
as an antagonist when exposed to high serotonergic activity, potentially increasing the risk for weight gain. In low
serotonergic environments, it may act as an agonist and have
the reverse effect. In this context, the presence of the serotonergic antidepressant would explain the weight gain seen
in the depression studies as opposed to the weight-neutral
effect seen in the schizophrenia studies. To test this hypothesis, they conducted a retrospective chart review of patients
prescribed aripiprazole with high serotonergic antidepressants (citalopram, paroxetine, sertraline, or venlafaxine)
versus bupropion, which has minimal effect on serotoninergic
activity. They noted a statistically significant mean increase
in weight among patients taking aripiprazole with high serotonergic antidepressant. In the aripiprazole plus bupropion
group, they noted a decrease in weight, although it was not
clinically significant.

Long-acting injectable antipsychotics
To produce LAI forms of the older, typical antipsychotics,
such as haloperidol and fluphenazine, a long-chain fatty
acid moiety, such as decanoate or enanthate, is added to the
drug, so it can be dissolved in sesame oil, which is used as
the delivery vehicle. The drug is absorbed from the surface
of the depot injection, and in the case of haloperidol, no
overlap with oral medication is required when a loading
dose strategy is used.35
Atypical LAI antipsychotics use water as the vehicle for
delivery. Risperidone, the first atypical LAI, is delivered in
the form of a biodegradable microsphere preparation.35,36
It has a similar side-effect profile as oral risperidone, and the
main challenges in the clinical setting have been the need
for refrigeration as well as the need to dose the medication
every 2 weeks.36 A period of overlap with oral medication
is required with LAI risperidone.
LAI olanzapine uses a pamoate moiety suspended in
water and does not require oral supplementation overlap.35
288
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The greatest clinical challenge has been postinjection delirium syndrome, characterized by sudden sedation, confusion,
slurred speech, altered gait, or unconsciousness following
delivery. Patients must be observed for 3 hours after receiving
an injection.35,36
Paliperidone is the active metabolite of risperidone
and is also available as an LAI preparation. It has a similar
adverse effect profile. Unlike risperidone, there is no need
for oral supplementation during the initial treatment phase.
An even greater advantage is that it can be given monthly,
and there is no need for refrigeration, which makes it easier
to handle.35,36
LAI aripiprazole was approved for the treatment of
schizophrenia in 2013.17 The contraindications, warnings,
precautions, and side effects of long-acting ones are similar to the oral formulation. Aripiprazole LAI is available
as a lyophilized powder, which needs to be reconstituted
with sterile water prior to administration. 17,35,36 Release
into the bloodstream is slow, and it requires 14 days of
overlap with oral aripiprazole to maintain a therapeutic
concentration.37
With LAI antipsychotics, the most important factor
that influences the pharmacokinetic behavior is absorption
from the injection site.36 With aripiprazole, the absorption
rate is slower than the elimination rate.38 This phenomenon,
in which the drug disposition is limited by absorption
rather than metabolism, is called “flip-flop kinetics.”36 The
half-life is dependent on release rather than elimination.39
Slow absorption is primarily due to the poor solubility of
the particles.36
Both aripiprazole and its major metabolite, dehydroaripiprazole, bind to albumin, and at therapeutic levels, they are
99% bound. Aripiprazole is metabolized by the P450 system,
mainly by isoenzymes 3A4 and 2D6. Dosing adjustments are
recommended when it is used with inhibitors of CYP3A4
(eg, ketoconazole) or inhibitors of CYP2D6 (eg, quinidine,
fluoxetine, and paroxetine). Reducing the dose by one-half
is appropriate when coadministering it with these agents.20
Carbamazepine, via induction of CYP3A4, may reduce
aripiprazole levels by as much as 70%.40 Consequently,
aripiprazole should generally not be used in combination
with inducers of CYP3A4.41 Caution is recommended when
aripiprazole is used with antihypertensive agents because of
its alpha adrenergic antagonism and potential to enhance the
effects of these agents.41 If this combination is used, patients
should be educated on the signs and symptoms of hypotension, and blood pressure should be carefully monitored. Use
in combination with benzodiazepines also carries the risk of
hypotension as well as excess sedation.41
Neuropsychiatric Disease and Treatment 2018:14
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No dosing adjustment is needed when aripiprazole is
used with valproate, and there are no significant reports of
any other interactions with P450 enzymes.41 Approximately
8% of Caucasians and 3% of African Americans are poor
metabolizers of CYP 2D6 substrates. In the clinical setting,
anyone with unusual side effects at low doses should be
considered a poor metabolizer.17 No dosing adjustments are
required based on sex, age, race, smoking status, and renal
or hepatic impairment.41

The efficacy of aripiprazole in the
treatment of bipolar disorder
There are several studies examining the safety and efficacy
of oral aripiprazole for the treatment of acute manic episodes of bipolar disorder. One large-scale prospective trial
enrolled 272 hospitalized patients in a double-blind, placebocontrolled, 3-week study. The primary outcome measure was
mean change in the Young Mania Rating Scale (YMRS).
Aripiprazole demonstrated superior efficacy to placebo in
the treatment of patients with bipolar I disorder presenting
with acute manic or mixed episodes.42 The discontinuation
rates due to adverse events were similar for aripiprazole and
placebo, and 80% of aripiprazole-treated patients maintained
the 30 mg/day target dose. A 2011 meta-analysis on the use of
aripiprazole for acute mania included a total of 2,333 patients
who took part in a randomized controlled trial.43 The number
needed to treat was 6 for response and 14 for remission at
week 3 of the study. On average, the response to aripiprazole
began at day 3, and suicide rates were found to be negligible
in all groups with mania.
Based on a post hoc analysis, aripiprazole appears to
be effective in people with rapid cycling bipolar disorder.
Twenty-eight patients with the rapid cycling subtype who
were treated with aripiprazole for a mixed or manic episode,
and then followed for 100 weeks experienced outcomes that
were similar to the non-rapid cycling participants.44
The efficacy of aripiprazole for the treatment of elevated
mood does not seem to be affected by the presence of mixed
symptoms. A post hoc analysis of a randomized, placebocontrolled trial that included 516 participants with acute
manic or mixed episodes found that aripiprazole was effective regardless of baseline depressive symptoms, which were
measured using the Montgomery Asberg Depression Rating
Scale (MADRS).45 Furthermore, aripiprazole significantly
reduced YMRS scores at the 3-week endpoint compared with
placebo in patients with more severe or less severe illness,
with or without psychotic features, and with or without a
history of rapid cycling. There was no significant difference
in response observed in men or women. Thus, aripiprazole
Neuropsychiatric Disease and Treatment 2018:14

Long-acting injectable aripiprazole in bipolar I

was found to be helpful across a range of subpopulations
experiencing acutely manic or mixed episodes.
Aripiprazole has not been found to be effective for the
treatment of bipolar depression. A 2008 multicenter, randomized, placebo-controlled study evaluated the efficacy and
safety of aripiprazole monotherapy in patients experiencing
a bipolar depressive episode without psychotic features.
The primary end point was mean change from baseline to
week 8 in the MADRS score. In this study, aripiprazole did
not achieve statistical significance versus placebo at week 8.46
Additional studies have reported similar results, indicating
that aripiprazole is not effective for treatment of acute bipolar
depressive episodes.43
In addition to its effectiveness for acute manic and mixed
episodes, aripiprazole oral formulation has also been found
to be effective in the maintenance treatment of bipolar disorder. The drug was granted approval for this indication by
the FDA in 2005. The pivotal study examining efficacy and
tolerability of aripiprazole for relapse prevention in bipolar
I disorder followed patients for 100 weeks.47 This longitudinal study featured 26 weeks of double-blind treatment with
either aripiprazole or placebo, with a primary endpoint of
time to relapse for any mood episode. At 100 weeks, time
to relapse was significantly longer with aripiprazole than
with placebo, specifically delaying time to manic relapse.
There was no significant difference between placebo and
aripiprazole in time to depressive relapse.
In addition to this longitudinal study, a 2011 metaanalysis also examined the efficacy of oral aripiprazole for
maintenance prevention of manic episodes in a population
who had been responsive to the medication for treatment
of acute decompensation.43 Researchers found the median
survival time (measured as time to any mood episode) for
the aripiprazole group to be longer than the study could
measure, while the median survival of the placebo group
was 118–203 days.43

LAI aripiprazole in schizophrenia
The first indication for LAI aripiprazole was for the treatment
of schizophrenia. A large study that enrolled 710 participants
examined the efficacy and tolerability of the LAI formulation in the maintenance phase of schizophrenia. Participants
entered the study during acute exacerbations, and were first
treated with open-label oral aripiprazole. Five hundred
seventy-six participants were able to receive LAI, and of
these, 403 were adequately stabilized and able to enter the
randomized, placebo-controlled phase of the study. LAI
aripiprazole was found to significantly delay time to relapse
in comparison with placebo.48 In another study, once-monthly
submit your manuscript | www.dovepress.com
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400 mg LAI aripiprazole was shown to be noninferior to the
oral formulation.49
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LAI aripiprazole in bipolar disorder
In July 2017, the FDA approved LAI aripiprazole for maintenance monotherapy of bipolar I disorder in adults. This
approval was based on a single study that included over
700 individuals. It utilized a diverse sample of participants
recruited from 103 sites in 7 countries.50 The outcome was
highly significant – both statistically and clinically. Nearly
twice as many LAI-treated participants remained stable for
the entire study compared to those treated with placebo.
As with any study, there are aspects that require the
clinician to use caution when applying the results to patient
care. An efficacy trial, in which the goal is to evaluate whether
a drug works better than placebo, is designed to maximize
internal validity, that is, the likelihood that the difference
between an effective drug and placebo will achieve statistical
significance. This design is an essential first step in the evaluation of a medication, but maximizing internal validity can
reduce the generalizability of the findings. One component
of this trade-off is subject selection.
Similar to the study of LAI in schizophrenia, this study
used an enriched study sample, enrolling participants who
had a greater than average chance of remaining stable on LAI.
Participants were selected based on their ability to transition,
one step at a time, from the medications they were taking at
study entry to monotherapy with oral aripiprazole and then
to LAI aripiprazole. Participants who became unstable at
any point along the way were removed from the study prior
to randomization.
The use of an enriched sample is standard practice in
bipolar disorder maintenance studies. Although it necessarily
limits the generalizability of the findings, it matches the
way medications are used in clinical practice. For example,
if a potential maintenance drug is used for acute stabilization and fails, clinicians are unlikely to continue it into the
maintenance phase of treatment.
In clinical trials, the specific inclusion criteria that are
used to enrich the sample may be more or less restrictive. In
this study, the first step was to ensure that the participants
who were taking other medications for bipolar disorder
could successfully transition to oral aripiprazole. Of the
731 people who were eligible for the study, 466 needed to be
transitioned (the others were either on aripiprazole already
or on nothing because of nonadherence). This phase of the
study lasted 4–6 weeks, and resulted in about a quarter of
the participants being removed from the study.
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The next phase was to select individuals who could be
stabilized on oral aripiprazole monotherapy. This phase
lasted 2–8 weeks, and caused about a third of the remaining
sample to be excluded.
After stabilization on oral aripiprazole, the third phase
required participants to transition to LAI, and maintain
stability on LAI monotherapy for at least 8 consecutive
weeks. Participants were given 400 mg of aripiprazole at
each monthly injection with the option to decrease the dose
to 300 mg if tolerability became a problem. Approximately
65% of those stabilized on the oral formulation remained
stable on LAI.
In all, 465 participants were removed from the study
because they did not do well while being transitioned from
their baseline treatment to LAI. The remaining 266 participants were eligible for randomization to either LAI continuation at 300 or 400 mg per month (mean dose 380 mg) or a
switch to placebo.
Although LAI aripiprazole was substantially more effective than placebo, only about half of the participants who
made it to the randomization phase and were given LAI
aripiprazole remained stable for the entire 52-week study
period. Among those who were randomized to placebo, a
little more than a quarter remained stable. These numbers
reflect the fact that bipolar disorder is a cyclic illness, and it
is unrealistic to expect maintenance treatment to eliminate
abnormal mood episodes completely. These results also
highlight the challenges of treating bipolar disorder with
monotherapy. In clinical practice, fewer than 20% of bipolar
patients are treated with mood stabilizer monotherapy. Most
require at least three medications.51 Further emphasizing the
need for combined therapy is LAI aripiprazole’s relative lack
of efficacy preventing depressive episodes.
Treatment-emergent adverse events were, for the most part,
mild to moderate. Akathisia was the most common adverse
event, which, combined with restlessness, was experienced
by 23% of the sample. Approximately 11% of participants
experienced weight gain, 10% insomnia, 7% anxiety, and
5% fatigue.

Conclusion
Although the data supporting LAI aripiprazole as an effective
treatment for the maintenance phase of bipolar disorder are
currently limited to a single study, the results were robust
enough to merit FDA approval for this indication. This is a
welcome development. Despite the numerous medications
that are available to treat this disorder, none is fully effective for all patients and the problem of long-term adherence
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remains a significant challenge. Future studies will be needed
to confirm the disappointing finding that LAI aripiprazole
does not seem to be more effective than placebo for the prevention of new depressive episodes. Additionally, combination treatment with lithium, anticonvulsant medications, and
other mood stabilizers should be investigated to determine
whether efficacy can be further improved. Combination with
lamotrigine would be of particular interest, given that medication’s unique efficacy in preventing depressive episodes
during maintenance.
In some ways, the maintenance phase is the most important phase of treatment. Acute manic episodes have the most
dramatic presentations, and acute depressive episodes, along
with long-term residual depressive symptoms, account for
the majority of disability experienced by people living with
bipolar disorder.52 However, it is during the maintenance
phase, when patients are relatively symptom-free, that they
live their lives. It is when they pursue their careers, develop
relationships, and discover their identity as a unique individual, separate from the personality-distorting symptoms
of the illness. Psychiatrists tend to focus on pathology;
however, only wellness can lead to recovery. Despite the
lack of symptomatology, maintenance is an aspect of the
bipolar disorder that deserves a high priority.
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